Floatz logo

Shr-9839

Solid Tumor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

479 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
Mirati Therapeutics Inc.
Phase 4BB
(+)-VINCRISTINE
Pfizer
Phase 4B
Atezolizumab
Hoffmann-La Roche
Phase 2/3B
Rivoceranib
Beidahuang Industry Group General Hospital
Phase 3B
Durvalumab
GlaxoSmithKline
Phase 4B

View all 50 →

Same molecule, other indications

Shr-9839 is also rated in:

cancerDormant
BB
Indicative ·
65 / 100
View asset →
Advanced Solid TumorsDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced KRAS G12D Mutant Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →